

INFORMATION DISCLOSURE STATEMENT

Applicants	: Kiyohiko, et al.
App. No.	: 10/564,302
Filed	: January 10, 2006
For	: DRUG FOR CANCER THERAPY
Examiner	: Sheela Jitendra Huff
Art Unit	: 1643
Conf. No.	: 7332

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing three (3) and enclosing two (2) references to be considered by the Examiner.

U.S. Patent No. 5,317,084 is the U.S. counterpart to JP5-238948A.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

Sept. 25, 2007

By:

Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404